Par Health Issues Voluntary Nationwide Recall of Argatroban Injection Due to the Presence of Particulate Matter
- Date
- Oct 13, 2026
- Company
- Par Health USA, LLC
- Brand
- Par Health and Endo USA
- Product
- Argatroban Injection 250 mg/2.5 mL (100 mg/mL)
- Reason
- Presence of particulate matter, identified as cellulose, polystyrene, polyethylene terephthalate, stopper material, and possibly stainless steel
- Hazard
- Other
- Source
- FDA
How to identify the product
- Argatroban Injection 250 mg/2.5 mL (100 mg/mL), Distributed by: Par Pharmaceutical* or Endo USA*
- These lots were distributed nationwide to wholesalers and hospitals between December 30, 2024, and May 5, 2026.
- Par Health is providing written notification to wholesale and hospital accounts that have received the affected lots and is arranging for return of all existing inventory through Inmar, Inc.
- If you have further distributed the recalled product, please notify your accounts or any additional locations which may have received the recalled product.
Product photos are on the official FDA page.
Facts are taken from the official notice. If anything here differs from it, the official notice is correct.